EP1558085A4 - Verfahren zur herstellung vonlymphozyten, die interleukin-2 exprimieren, sowie ihre verwendung bei derbehandlung von krebs - Google Patents

Verfahren zur herstellung vonlymphozyten, die interleukin-2 exprimieren, sowie ihre verwendung bei derbehandlung von krebs

Info

Publication number
EP1558085A4
EP1558085A4 EP02789213A EP02789213A EP1558085A4 EP 1558085 A4 EP1558085 A4 EP 1558085A4 EP 02789213 A EP02789213 A EP 02789213A EP 02789213 A EP02789213 A EP 02789213A EP 1558085 A4 EP1558085 A4 EP 1558085A4
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
lymphocytes expressing
expressing interleukin
obtaining lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02789213A
Other languages
English (en)
French (fr)
Other versions
EP1558085A1 (de
Inventor
Ke Liu
Steven A Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP1558085A1 publication Critical patent/EP1558085A1/de
Publication of EP1558085A4 publication Critical patent/EP1558085A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP02789213A 2002-10-15 2002-10-15 Verfahren zur herstellung vonlymphozyten, die interleukin-2 exprimieren, sowie ihre verwendung bei derbehandlung von krebs Ceased EP1558085A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/033243 WO2004034789A1 (en) 2002-10-15 2002-10-15 Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
EP1558085A1 EP1558085A1 (de) 2005-08-03
EP1558085A4 true EP1558085A4 (de) 2006-12-06

Family

ID=32105950

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02789213A Ceased EP1558085A4 (de) 2002-10-15 2002-10-15 Verfahren zur herstellung vonlymphozyten, die interleukin-2 exprimieren, sowie ihre verwendung bei derbehandlung von krebs

Country Status (4)

Country Link
EP (1) EP1558085A4 (de)
AU (1) AU2002353822B2 (de)
CA (1) CA2501087C (de)
WO (1) WO2004034789A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005336093B2 (en) 2004-10-08 2011-02-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Adoptive immunotherapy with enhanced T lymphocyte survival
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693940B1 (de) * 1993-04-06 2002-11-13 Targeted Genetics Corporation Hybride gene zur verwendung in der herstellung von helfer-t-zell-unabhängigen zytotoxischen t-zellen
WO1999046392A1 (en) * 1998-03-12 1999-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DETRAIT E. R. ET AL: "Reporter gene transfer induces apoptosis in primary cortical neurons", MOLECULAR THERAPY, vol. 5, no. 6, June 2002 (2002-06-01), pages 723 - 730, XP002258886 *
DOI K ET AL, VISION RES, vol. 42, 2002, pages 551 - 558 *
HANAZONO Y ET AL: "Primary T lymphocytes as targets for gene therapy", JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, vol. 9, no. 5, 2000, pages 611 - 620, XP008098208 *
KAMMULA U S ET AL: "Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens.", JOURNAL OF IMMUNOLOGY, vol. 163, 1999, pages 6867 - 6875 *
LIU K ET AL, J IMMUNOTHERAPY, vol. 26, 2003, pages 190 - 201 *
LIU K. ET AL: "Transduction of an IL-2 gene into human melanoma tumor infiltrating lymphoyctes (TILs) results in their continued growth in the absence of exogenous IL-2 after the destruction of autologous tumor cells in vitro", PROC AM SOC CLIN ONCOL, vol. 21, 2002, Retrieved from the Internet <URL:http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=16&abstractID=71> [retrieved on 20070613] *
LIU K. ET AL: "Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity", JOURNAL OF IMMUNOLOGY, vol. 167, no. 11, 2001, pages 6356 - 6365, XP002435508 *
ROSENZWEIG M ET AL, BLOOD, vol. 97, 2001, pages 1951 - 1959 *
SCHOLL S M ET AL: "Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.", JOURNAL OF IMMUNOTHERAPY (HAGERSTOWN, MD. : 1997) 2000 SEP-OCT, vol. 23, no. 5, September 2000 (2000-09-01), pages 570 - 580, XP008009925, ISSN: 1524-9557 *
See also references of WO2004034789A1 *
STRIPECKE R. ET AL: "Immune response to green fluorescent protein: Implications for gene therapy", GENE THERAPY, vol. 6, 1999, pages 1305 - 1312, XP003002920 *
TREVOR KATRINA T ET AL: "Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 50, no. 8, October 2001 (2001-10-01), pages 397 - 407, XP002403442, ISSN: 0340-7004 *
WANG E ET AL: "T-cell-directed cancer vaccines: the melanoma model.", EXPERT OPINION ON BIOLOGICAL THERAPY. MAR 2001, vol. 1, no. 2, March 2001 (2001-03-01), pages 277 - 290, XP009052140, ISSN: 1471-2598 *

Also Published As

Publication number Publication date
CA2501087C (en) 2012-01-03
AU2002353822A1 (en) 2004-05-04
WO2004034789A1 (en) 2004-04-29
AU2002353822B2 (en) 2008-11-06
EP1558085A1 (de) 2005-08-03
CA2501087A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
FR2854074B1 (fr) Utilisation de l&#39;ivermectine pour le traitement de desordres dermatologiques
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d&#39;etats pathologiques
EP1689348A4 (de) Oligosaccharid-zusammensetzungen und ihre verwendung bei der behandlung von infektionen
FR2794036B1 (fr) Procede et appareil pour accentuer le nettoyage de chambre de traitement
EP1604664A4 (de) Medikament zur vorbeugung und behandlung von arteriosklerose und bluthochdruck
FR2775078B1 (fr) Procede et dispositif pour le traitement de vaisselle dans des lave-vaisselle
MA29084B1 (fr) Derives d&#39;indenyle et leur utilisation dans le traitement de troubles neurologiques
EP1194927A4 (de) Kombiniertes fertiggestelltes und beschreibbares medium und verwendung in einer anwendung im internet als elektronisches buch
GB9925804D0 (en) Biological materials and method useful in the diagnosis and treatment of diseases
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l&#39;usage pour la prevention ou le traitement de la hyper-oxalurie
FR2767476B1 (fr) Dispositif physiotherapeutique pour le traitement de la peau par aspiration sous vide et ultrasons
EP1311261A4 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
IL162678A0 (en) N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
EP1575577A4 (de) Zusammensetzung zur vermeidung und behandlung von ohrenentzündungen
FR2812197B1 (fr) Utilisation de co dans le traitement de l&#39;inflammation des voies aeriennes superieures ou des bronches
IT1320860B1 (it) Apparecchiatura per il trattamento di disgregazione di campionibiologici e dispositivo disgregatore per l&#39;impiego in detta
FR2840307B1 (fr) Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
EP1085906A4 (de) Antikörper gegen zytokine zur vorbeugung und behandlung entzündlicher darmerkrankungen
DE60032910D1 (de) Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3
EP1572887A4 (de) Nervenregenerierungspeptid und verfahren zu deren verwendung bei der behandlung einer hirnschädigung
EP1750513A4 (de) Verwendung von gpcr54-liganden zur behandlung von unfruchtbarkeit
EP1621214A4 (de) Material zur behandlung schädlicher substanzen und verfahren und gerät zur behandlung schädlicher substanzen
EP1558085A4 (de) Verfahren zur herstellung vonlymphozyten, die interleukin-2 exprimieren, sowie ihre verwendung bei derbehandlung von krebs
EP1161255A4 (de) Verfahren und mittel zur behandlung erektiler dysfunktion
FR2839254B1 (fr) Valet d&#39;aide pour l&#39;habillage ou le deshabillage notamment des personnes souffrant d&#39;un handicape et vetement associe

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20061108

17Q First examination report despatched

Effective date: 20070622

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090817